Abstract: Electronic apparatus includes functional circuitry configured to respond to requests from a plurality of client devices, data storage circuitry configured as a plurality of client queues in which each respective client queue is configured to store pending requests from a respective client device, priority determination circuitry configured to assign a respective priority level to each respective client queue based at least in part on requests stored in the respective client queues, and arbiter circuitry configured to control access to the functional circuitry by the plurality of client devices. The arbiter circuitry is configured to monitor the priority level of each respective client queue, and control passage of requests from client queues to the functional circuitry based at least in part on a respective priority level assigned to each respective client queue. The priority determination circuitry includes fill level detector circuitry configured to determine a fill level of each client queue.

Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.

Abstract: A network device includes queues for queuing packets, and functional circuitry to provide a processing resource to be shared by the queues. Further, the network device includes a first-in-first-out (FIFO) selection circuit that receives tokens respectively associated with the queues. The FIFO selection circuit buffers and outputs the tokens in a first-in-first-out manner. When a token is output by the FIFO selection circuit, a queue associated with the token is selected to provide a packet for the functional circuitry to process. When a queue associated with an output token having at least a second packet in the queue after the queue outputs a first packet, the FIFO selection circuit re-buffers the output token associated with the queue to permit the queue to output the second packet once the output token associated with the queue is again output by the FIFO selection circuit.

Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.

Abstract: A FIFO memory device has a first number of data storage units and a second number of internal FIFO memories. Each internal FIFO memory has a third number of internal data storage units. The first number is a product of the second and third numbers. A fourth number of data inputs receives input data units in order. Input multiplexer circuitry connects each one of the data inputs to any one of the internal FIFO memories, for storage of input data units, in order, in a first layer of the FIFO memory device including corresponding storage locations in respective ones of the internal FIFO memories. The first layer may be physical, or may be logical and maintained by pointers. Output multiplexer circuitry coupled to the internal FIFO memories connects each of the internal FIFO memories to any one of the data outputs to read out the stored data units in order.

Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.

Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.

Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.

Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.

Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.

Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.

Abstract: Multimeric protein structures are disclosed herein, as well a process for preparing same, and methods employing same for treating various diseases or disorders. The multimeric protein structures comprise at least two monomers of a therapeutic protein, including a TNF-alpha, a luteinizing hormone, an immunoglobin, a TNF-alpha receptor, a CTLA-4, a urate oxidase, a VEGF, a PDGF, a VEGF receptor, a PDGF receptor, an interleukin-17, and/or fragments thereof, the monomers being covalently linked to one another via a linking moiety. The multimeric protein structures exhibit improved performance as compared to the corresponding native proteins, including a longer lasting activity in vivo.

Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.

Abstract: A method of treating Fabry is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of alkaline alpha galactosidase, thereby treating Fabry disease.